JOHANNESBURG - Professor of Vaccinology at the University of the Witwatersrand Shabir Madhi said the benefits of using the Johnson & Johnson vaccine far outweigh the risks.
He says while pausing the clinical trial is justified, the vaccine should be rolled out.
The trial was halted while the SA Health Products Regulatory Authority examines data on a possible link between the jab and a rare blood clot disorder.
"The decision by the government to pause the J&J vaccine needs to be contextualised in that the vaccine is used as a clinical trial. In this clinical trial, the participants need to always to informed of any risks.
"There's been a pause on the clinical trial which is justified because investigators need to do the necessary paperwork.
"As the J&J arrives tomorrow, I think it would be a huge miscalculation not to immediately start the use of the vaccine.
"SA is one of the countries where there is still a significant amount of the transmission of the virus and the risk-benefit ratio is in favour of continuing the vaccination program rather than delaying the use of the vaccine."